MX2007005469A - Derivados tric??clicos de guanidina como inhibidores del intercambio de sodio-prot??n. - Google Patents

Derivados tric??clicos de guanidina como inhibidores del intercambio de sodio-prot??n.

Info

Publication number
MX2007005469A
MX2007005469A MX2007005469A MX2007005469A MX2007005469A MX 2007005469 A MX2007005469 A MX 2007005469A MX 2007005469 A MX2007005469 A MX 2007005469A MX 2007005469 A MX2007005469 A MX 2007005469A MX 2007005469 A MX2007005469 A MX 2007005469A
Authority
MX
Mexico
Prior art keywords
sodium
proton exchange
guanidine derivatives
exchange inhibitors
crarb
Prior art date
Application number
MX2007005469A
Other languages
English (en)
Inventor
Bansi Lal
Usha Ghosh
Swati Bal-Tembe
Arun Kumar Jain
Tulsidas More
Anil Ghate
Jacqueline Trivedi
Sapna Parikh
Original Assignee
Nicholas Piramal India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Piramal India Ltd filed Critical Nicholas Piramal India Ltd
Publication of MX2007005469A publication Critical patent/MX2007005469A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C07D327/08—[b,e]-condensed with two six-membered carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se describen derivados de guanidina que tienen un anillo triciclico condensado de formula 1: (ver formula 1) en donde U es C(O), CRaRb, O, NRa o S(O)m, V es CRaRb o NRa; W es S(O)n; en donde Ra es H, alquilo, cicloalquilo, alquenilo o aralquilo; Rb es H, alquilo, OH, ORa o OCORa, y m es el entero 0, 1 o 2; R1, R2, R3, R4, R5, R6, R7 y R8 son como se define en la presente, con la condicion de que al menos uno de R1, R2, R3, R4, R5, R6, R7 o R8 es guanidino o guanidino carbonilo. Estos derivados son inhibidores del intercambio sodio-proton y son utiles como medicamentos para el tratamiento de, por ejemplo, trastornos de los organos asociados con la isquemia y reperfusion, arritmia cardiaca, hipertrofia cardiaca, hipertension, trastornos proliferativos celulares y diabetes.
MX2007005469A 2004-11-10 2005-11-08 Derivados tric??clicos de guanidina como inhibidores del intercambio de sodio-prot??n. MX2007005469A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1225MU2004 2004-11-10
US63720804P 2004-12-17 2004-12-17
PCT/IB2005/053653 WO2006051476A1 (en) 2004-11-10 2005-11-08 Tricyclic guanidine derivatives as sodium-proton exchange inhibitors

Publications (1)

Publication Number Publication Date
MX2007005469A true MX2007005469A (es) 2007-07-10

Family

ID=38006671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005469A MX2007005469A (es) 2004-11-10 2005-11-08 Derivados tric??clicos de guanidina como inhibidores del intercambio de sodio-prot??n.

Country Status (16)

Country Link
US (2) US7834001B2 (es)
EP (1) EP1812420A1 (es)
JP (1) JP4921375B2 (es)
KR (1) KR20070106980A (es)
CN (2) CN102952112A (es)
AR (1) AR053312A1 (es)
AU (1) AU2005303409B2 (es)
BR (1) BRPI0516704A (es)
CA (1) CA2587620A1 (es)
IL (1) IL183086A0 (es)
MX (1) MX2007005469A (es)
NZ (1) NZ554936A (es)
RU (1) RU2390521C2 (es)
TW (1) TW200614995A (es)
WO (1) WO2006051476A1 (es)
ZA (1) ZA200703756B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200615273A (en) * 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
EP2346836B1 (en) * 2008-10-08 2018-03-07 Cephalon, Inc. Processes for the preparation of bendamustine
KR20140003484A (ko) * 2011-02-02 2014-01-09 아스테라스 세이야쿠 가부시키가이샤 테트라히드로이소퀴놀린 유도체
RU2558087C2 (ru) * 2013-10-22 2015-07-27 Сергей Владимирович Шумилин Способ управления нефтегазовым месторождением
RU2558088C2 (ru) * 2013-10-23 2015-07-27 Сергей Владимирович Шумилин Способ управления нефтегазовой скважиной
EP3587391A1 (en) 2018-06-22 2020-01-01 Basf Se Process for preparing nitrobenzyl bromides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2094790B (en) * 1981-03-13 1985-10-09 Spofa Vereinigte Pharma Werke Tricycle compounds
US5036067A (en) * 1990-03-14 1991-07-30 Merck & Co., Inc. Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
EP0589336B1 (de) 1992-09-22 1997-01-08 Hoechst Aktiengesellschaft Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika
DE4437874A1 (de) 1994-10-22 1996-04-25 Merck Patent Gmbh Alkyl-5-methylsulfonyl-benzoylguanidin-Derivate
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19548708A1 (de) 1995-12-23 1997-06-26 Merck Patent Gmbh Cyclische Sulfone
DE19621483A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JPH10152481A (ja) * 1996-09-25 1998-06-09 Kanebo Ltd ベンゾ［１，４］チアジン誘導体およびそれからなる医薬
FR2765580B1 (fr) 1997-07-01 1999-08-06 Synthelabo Derives de (1h-imidazol-4-yl)piperidine, leur preparation et leur application en therapeutique
EP1180029A4 (en) * 1999-04-23 2002-10-02 Bristol Myers Squibb Co BICYCLIC ACYL IHIBITORING SODIUM / PROTON EXCHANGER AND RELATED PROCEDURE.
DE10204989A1 (de) * 2002-02-07 2003-08-21 Aventis Pharma Gmbh Dihydro-thia-phenanthren-carbonyl-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
AU2005303409B2 (en) 2011-12-15
NZ554936A (en) 2010-09-30
WO2006051476A1 (en) 2006-05-18
JP4921375B2 (ja) 2012-04-25
RU2007121681A (ru) 2008-12-20
TW200614995A (en) 2006-05-16
JP2008519823A (ja) 2008-06-12
IL183086A0 (en) 2007-09-20
US7834001B2 (en) 2010-11-16
US8183234B2 (en) 2012-05-22
RU2390521C2 (ru) 2010-05-27
AU2005303409A1 (en) 2006-05-18
US20070299051A1 (en) 2007-12-27
BRPI0516704A (pt) 2008-09-16
ZA200703756B (en) 2008-06-25
CN101076526A (zh) 2007-11-21
US20100267690A1 (en) 2010-10-21
EP1812420A1 (en) 2007-08-01
KR20070106980A (ko) 2007-11-06
AR053312A1 (es) 2007-05-02
CN102952112A (zh) 2013-03-06
CA2587620A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
MX2007005469A (es) Derivados tric??clicos de guanidina como inhibidores del intercambio de sodio-prot??n.
EP2206709A3 (en) Thiophene derivatives as antiviral agents for flavivirus infection
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
BRPI0413232A (pt) novos compostos tendo atividade inibitória contra os trasnportadores dependentes de sódio
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
DE60228406D1 (de) PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS
TW200505453A (en) Non-nucleoside reverse transcriptase inhibitors
BR0207809A (pt) Compostos heteroarila contendo nitrogênio possuindo atividade inibidora contra integrase de hiv
MY144718A (en) Viral polymerase inhibitors.
MY135841A (en) Novel benzodioxoles
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
HRP20130075T1 (hr) S-TRIAZOLIL ALFA-MERKAPTOACETANILIDI KAO INHIBITORI REVERZNE TRANSKRIPTAZE HIV-a
AP2003002841A0 (en) Quinazolines as MMP-13 inhibitors
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
EP1813270A4 (en) PROTEIN INHIBITORS OF THE HSP90 FAMILY
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
NZ512658A (en) Heterocyclic-substituted diphenylurea derivatives and pharmaceutical compositions containing them
CA2336412A1 (en) Medicament for treatment of diabetes
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
ATE517626T1 (de) Aminosubstituierte sulphonanilide und ihre derivate zur behandlung von proliferativen erkrankungen
DE69702419D1 (de) Substituierte Guanidin Derivate und ihre Verwendung als Na+/H+ Austausch Inhibitoren
BRPI0409995A (pt) composto, e, agente anti-leishmánia
WO2004065360A3 (en) Piperazine derivatives and their use as synthesis intermediates
ES2180201T3 (es) Derivados de azetidinona para el tratamiento de infecciones por hcmv.

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status